DICHIARAZIONE SOSTITUTIVA DELL'ATTO DI NOTORIETA'
(Art. 47 D.P.R. 28 dicembre 2000, n. 445)

La sottoscritta ORGIANO LAURA Nata a [redacted] residente a [redacted] (CA) in [redacted]

consapevole delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi, richiamate dall'art. 76 del D.P.R. 445 del 28 dicembre 2000

DICHIARA

Che le informazioni sotto riportate sono veritiere:

WORK EXPERIENCE

19th Aug 22 – Today	Medical Oncologist at University Hospital AOU Cagliari,
3rd Oct 21 – 25th Jan 23	II Level Master on Immunooncology (La Sapienza University, Roma)
1st Jul 20 – 24th Nov 21	II Level Master on Public Health and Clinical Management (LUM University, Casamassima (BA)
23rd Mar 20 - 18th Aug 22	Medical Oncologist at San Martino Hospital, Oristano (permanent)
1st Oct 18 – 22nd Mar20	Medical Oncologist at San Martino Hospital, Oristano (temporary)
16th Oct 14- 13rd Feb 18	Phd on Molecular and Translational Medicine, University of Cagliari (3 y)
6th Feb -19th Jul 2017	Medical Oncologist at NS Mercede Hospital, Lanusei
3rd Oct -13rd Nov 2016	Medical Oncologist at Businco Hospital, Cagliari
4th Jul 14- 18th May 2015	Medical Oncologist, Full time contract Genoa University, AOU San Martino, Department of Medical Oncology
1st Jan-03rd Jul 2014	Clinical Research, Clinical trials and research on melanoma patients Genoa University, AOU San Martino, Department of Medical Oncology
1st Apr – 31st Dec 2013	Sperimental Laboratory Research Cambridge University, Department of Obstetrics and Gynecology, Addenbrookes' Hospital (Prof. Francesco Colucci), Cambridge, UK Experimental Immunology research on the interactions between the immune system (NKcells) and melanoma: study on human and murine patterns
30th Jun 09-3rd July 14	Post-degree School of Specialization in Medical Oncology

(total duration: 5 years) University of Cagliari, Faculty of Medicine and Surgery, AOU Cagliari -University Hospital, Monserrato (CA).
Date of Specialization: 3rd July 2014, discussion of the thesis titled: " An open label, multicenter expanded access study of VEMURAFENIB in patients with metastatic melanoma BRAF V600 positive".
Final vote: 50/50 cum Laude

From 24th February 2009 — Enabling of the Medical Profession and subsequent registration to Register of Professional Medical Association of Cagliari, position n ° 9167

1st Oct 2006- 31stMar2007 — Activity of tutoring medical students enrolled in the first, second and third year of the Medicine Clinical School, Cagliari
Assistance to students during the study, recovery activities and preparation for examinations under the Study Plan

6thSept 2002- 23rdJul 2008 — Master Degree in Medicine and Surgery, University of Cagliari
Discussion of the thesis titled: "Hyperthermic intraperitoneal chemotherapy (HIPEC): analysis of impact on cellular and immunological characteristics of the ascitis, on the clinical response and the quality of life of patients with peritoneal carcinomatosis from primary tumors of different origin".
Final vote: 110/110 cum Laude and Academic Mention

Sept 1997- 28th Jun 2002 — Scientific High School "A. Pacinotti", Cagliari High school licence
Final vote: 100/100 with note of Merit of the Jury

PERSONAL SKILLS

Mother tongue: Italian

Other language: English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
Replace with language: C1	C1	C1	C1	C1
Replace with language: C1	C1	C1	C1	C1

Replace with name of language certificate. Enter level if known.

Communication skills: GOOD ABILITY TO REPORT AND COLLABORATION IN THE ACTIVITIES OF THE GROUP AND INTERDISCIPLINARY. GOOD CAPACITY of COMMUNICATION AND FITNESS FOR GOOD AND PREPARING TO WORK IN TERMS OF STRESS

Organisational / managerial skills: GOOD CAPACITY OF SELF-EMPLOYMENT AND COLLABORATION WITH COLLEAGUES. GOOD CAPACITY OF LISTENING AND RESOLUTION OF DIFFICULTY', LOGISTICS AND MATERIALS.
COMPLIANCE WITH DEADLINES AND DELIVERY.

Computer skills

GOOD KNOWLEDGE OF HARDWARE.
OPERATING SYSTEMS: WINDOWS XP, WINDOWS VISTA, WINDOWS7
APPLICATIONS: Office, Internet Explorer and Outlook Express

Driving licence B Drive Licence (2nd August 2002)

ADDITIONAL INFORMATION

Memberships
2012: AIOM (Italian Association of Medical Oncology)
2012: ESMO (European Association of Medical Oncology)
2013: ASCO (American Association of Medical Oncology)
2014: IMI (Italian Melanoma Intergroup)

Conferences Participation in several national and international conferences.

Other Certifications BLSD Certificate (07/07/2015)

ESMO grants:

- ESMO – ASIA Conference, 16-19 December 2016, Singapore
- ESMO Symposium on Immuno-Oncology, 15-16 November 2013, Geneva, Switzerland
- Translational Research Unit Visit (Prof. F. Ciardiello), 3-6 February 2015 Naples, Italy
- ESMO Symposium on Signalling Pathways in Cancer 2015 – Targeting the MAPK pathway: From RAS to MEK, 13-14 March 2015, Barcelona, Spain
- ESMO Academy 2015, 28-30 August 2015, Oxford, UK
- ESMO Preceptorship on Immuno-oncology, 1-3 October 2015, Prague, Czech Republic

Involved as sub-investigator in the following national and international clinical trials:

- **ALLTO**: Phase III trial will compare lapatinib and trastuzumab in preventing recurrence after surgery and chemotherapy;
- **STARS**: A Prospective Multinational Observational Study to assess Health Resource Utilization associated with skeletal related events in patients with bone metastases secondary to breast, prostate or lung cancer or multiple myeloma;
- **TOSCA**: Phase II/III Randomised study, open label, multicenter comparing 3 months therapy of FOLFOX-4 vs 6 months therapy of FOLFOX-4 + Bevacizumab in adjuvant setting in high risk Stage II/ Stage III affected by colorectal cancer;
- **Short HER**: adjuvant treatment 3 months therapy Trastuzumab vs 12 months therapy Trastuzumab associated with two different chemotherapy regimens in HER2 postive breast cancer;
- **Head & Neck H&N07**: Neoadjuvant Docetaxel, CisplatinCOLUMBUS (and 5-Fluorouracil (TPF) followed by Radiotherapy plus Concomitant Chemotherapy or Cetuximab versus Radiotherapy plus Concomitant Chemotherapy or Cetuximab in patients with locally advanced Squamous cell Carcinoma of the Head and Neck. A randomised phase III factorial study
- **The NEMO trial (NRAS melanoma and MEK inhibitor)**: a randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma

- **COLUMBUS (COmbined LGX818 Used with MEK162 in BRAF mutant Unresectable Skin cancer)**: A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma
- **BRF115532 (COMBI-AD):** a phase III randomized double blind study of dabrafenib in COMBInation with trametinib versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection
- **BOOST (Basing Observation on Overall Survival as a Target):** overall survival of BRAF V600 mutated and non mutated metastatic melanoma patients: a cohort observational study of BRAF inhibitors and current therapies effectiveness
- **STEVIE** (A Single-arm, Open-Label, PhaseII, Multicenter Study to assess the Safety of Vismodegib(GDC-0449) in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma)
- **INTUITION:** INternational STUdy on Ipilimumab Treatment utilizatION in real world clinical practice(Real world ipilimumab utilization patterns, clinical outcomes and health care resource utilization in advanced cutaneous melanoma patients)
- **CHARLIE** (A5481056): Treatment Patterns and Outcomes for Patients with Metastatic Breast Cancer: A Retrospective Chart Review in Select Countries
- **FRIDA** (REP0114): A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic TripleNegative Breast Cancer

Teaching Roles:

- Tutor for Medicine undergraduate students (III year, Semeiotics): AA 2017/2018, **40** hours
- Tutor for Medicine undergraduate students (III year, Semeiotics): AA 2016/2017, **40** hours
- Tutor for Medicine undergraduate students (III year, Gastroenterology): AA 2016/2017, **120** hours
- Tutor for Medicine undergraduate students (III year, Internal Medicine): AA 2015/2016, **40** hours
- Tutor for Medicine undergraduate students (III year, Semeiotics): AA 2015/2016, **120** hours
- Tutor for Medicine undergraduate students (I-III year of Graduate Course): AA 2006/07, **100** hours

Publications (in extenso)

1) Ribero S, Stucci LS, Marra E, Marconcini R, Spagnolo F, Orgiano L, Picasso V, Queirolo P, Palmieri G, Quaglino P, Bataille V. Effect of Age on Melanoma Risk, Prognosis and Treatment Response. Acta Derm Venereol. 2018 Apr 12.

2) Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Guardo LD, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P; Italian Melanoma Intergroup (IMI). Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018 Jan 3.

3) Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M. The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? Target Oncol. 2016 May 17.

4) Orgiano L, Pani F, Astara G, Madeddu C, Marini S, Manca A, Mantovani G. The role of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.

Supportive Care in Cancer. 2016 May 12

5) Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol. 2015 Nov 13.

6) Barisione G, Fabbi M, Gino A, Queirolo P, Orgiano L, Spano L, Picasso V, Pfeffer U, Mosci C, Jager MJ, Ferrini S, Gangemi R. Soluble c-Met: a new candidate biomarker of metastatic uveal melanoma. JAMA Ophtalmology, May 2015

7) Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V, Queirolo P. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. OncoTargets and Therapy, 16 Jan 2015

8) Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of Oncology, 23 Dec 2014

9) Tan T, Pangigadde P, Sabbatino F, Favoino E, Orgiano L, Ferrone S, Carbone E, Colucci F. Harnessing host innate immunity may combat acquired resistance to BRAFi. Journal of Translational Medicine 2014, 12 (Suppl 1):O10

Publications (abstracts)

1) Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo, Di Guardo, Loi C, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, Natoli C, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. Annals of Oncology, vol 27 suppl 9, 409P (selected as poster during I ESMO-ASIA Conference 16-19 Dec 2016)

2) Orgiano L., Dessì A., Cubeddu A., Lai E., Mascia R., Tolu S., Palmas V., Camboni T., Madeddu C., Massa E., Astara G., Manzin A., Scartozzi M. CREAM Study: Clinical correlation between ipilimumab related colitis and intestinal microbiote in metastatic melanoma patients. Annals of Oncology, vol 27 suppl 9, 403 TiP (selected as poster during I ESMO-ASIA Conference 16-19 Dec 2016)

3) Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo, Di Guardo, Loi C, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, Natoli C, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. Annals of Oncology, vol 27 suppl 4, (poster at ESMO ASIA 2016)

4) Demurtas L., Lai E., Cubeddu A., Puzzoni M., Pusole G., Tolu S., Dessì A., Mascia R., Pusceddu V., Astara G., Orgiano L., Massa E., Scartozzi M. REINVENT: regorafenib Translational evaluation angiogenesis protocol. Annals of Oncology vol 27 suppl 6 (ESMO 2016 Abstr 603 TiP)

5) Pusole G., Puzzoni M., Mascia R., Demurtas L., Dessì A., Cubeddu A., Lai E., Tolu S., Ziranu P., Orgiano L., Pusceddu V., Astara G., Madeddu C., Massa E., Casula L., Palmieri G., Scartozzi M. Selection with a molecular panel for panitumumab efficacy in K-ras and N-ras wild type metastatic colorectal cancer (SUPER-PEAK). Annals of Oncology vol 27 suppl 6 (ESMO 2016 Abstr iv52)

6) Dessì A., Demurtas L., Tolu S., Puzzoni M., Cubeddu A., Lai E., Pusole G., Mascia R., Ziranu P., Orgiano L., Pusceddu V., Astara G., Madeddu C., Massa E., Casula L., Scartozzi M. REINVENT: regorafenib Translational evaluation angiogenesis protocol. Annals of Oncology vol 27 suppl 4 (ESMO 2016 Abstr iv53)

7) Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo, Di Guardo, Loi C, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, Natoli C, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. Annals of Oncology, vol 27 suppl 9, (ESMO 2016, Abstr iv89)

8) Pani F., Orgiano L., Massa E., Boi F., Astara G., Pusceddu V., Scartozzi M., Mariotti S. Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. ETA 2016, 39th Annual Meeting of the European Thyroid Association, 3-6 september 2016

9) Pani F., Orgiano L., Massa E., Boi F., Astara G., Pusceddu V., Scartozzi M., Mariotti S. Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. ETA 2016, 39th Annual Meeting of the European Thyroid Association, 3-6 september 2016

10) Orgiano L, Bruder F, Madeddu C, Marconcini R, Gambale E, Galizia E, Stucci S, Spagnolo, Di Guardo, Loi C, Pani F, Massa D, Massa E, Astara G, Del Vecchio M, Silvestris F, Natoli C, Falcone A, Queirolo P, Scartozzi M. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. ASCO Annual Meeting, Chicago (US) 3rd-7th June 2016. Abstr e21009

11) Orgiano L, Pani F, Pusceddu V, Astara G, Madeddu C, Massa E, Cubeddu A, Demurtas L, Dessì A, Lai E, Mascia R, Tolu S, Pusole G, Puzzoni M, Boi F, Mariotti S, Scartozzi M; Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. ASCO Annual Meeting, Chicago (US) 3rd-7th June 2016. Abstr e15004

12) Orgiano L., Dessì A., Astara G., Madeddu C., Massa E., Pusceddu V., Palmieri G., Scartozzi M. A new way to fight early recurrences: We need it, we'll find it! Abstract 51Tip (selected for poster presentation), ESMO-ASIA 2015 Congress, 18th – 21st December 2015

13) Orgiano L., Cubeddu A., Demurtas L., Dessì A., Mascia R., Pusole MG., Puzzoni M., Astara G, Madeddu C., Massa E., Pusceddu V., Palmieri G., Scartozzi M. From needle to blood: the potential key role of liquid biopsy as early marker of relapse in patient with metastatic melanoma. Poster presentation at XXI IMI Annual Meeting. Genove, 18th-20th October 2015

14) L. Orgiano, A.Dessì, L. Demurtas, A. Cubeddu, M.G. Pusole, M. Puzzoni, R. Mascia, G. Astara, C. Madeddu, E. Massa, V. Pusceddu, M. Scartozzi. The liquid biopsy as a new ally to fight cancer? Abstract R61. XVII AIOM Annual Meeting. Rome, 23rd-25th October 2015

15) P. Queirolo, F. Spagnolo, V. Picasso, E. Tornari, V. Ottaviano, L. Orgiano, L. Giorello, D.F. Merlo, A. M. Grimaldi, E. Simeone, M. Curvietto, P. A. Ascierto and P. Bruzzi. BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine; selected for poster presentation at annual SMR Meeting, Zurich, 13rd-16th November 2014

16) P. Queirolo, F. Spagnolo, V. Picasso, E. Tornari, V. Ottaviano, L. Orgiano, L. Giorello, D.F. Merlo, A. M. Grimaldi, E. Simeone, M. Curvietto, P. A. Ascierto and P. Bruzzi. BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine; selected for oral comunication at II IMI Meeting, 5th -7th October 2014, Treviso

17) Tan T, Pangigadde P, Sabbatino F, Favoino E, Orgiano L, Ferrone S, Carbone E, Colucci F. Harnessing host innate immunity may combat acquired resistance to BRAFi. Oral Presentation at Melanoma Bridge meeting 5-8 December 2013, Naples, Italy

18) Ziranu P, Frau B, Puzzoni M, Murgioni S, Muntoni M, Cau MC, Mascia R, Pusole G, Dessì A, Cogoni C, Cubeddu A, Loi C, Orgiano L, Defraia S, Serci C, Astara G, Atzori F, Massa E, Madeddu C, Pusceddu V and Ionta MT. Bevacizumab related toxicity in metastatic colorectal cancer (mCRC). A single institution experience. XV Congresso Nazionale AIOM , Milano 11-13 Ottobre 2013

19) C. Madeddu, A. Maccio', G. Antoni, R. Serpe, L. Orgiano, E. Lai, I. Omoto, G. Mantovani; PP101-MON an effective and safe two-drug combination regimen for cancer-related cachexia; September 2013, Clinical Nutrition Vol. 32Supplement 1, Page S160

20) Giovanni Mantovani, Mariele Dessi, Laura Orgiano, Alessandra Piras, Christian Cadeddu, Martino Deidda, Massimo Ghiani, Giorgia Antoni, Roberto Serpe, Giuseppe Mercuro; Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). Journal of Clinical Oncology 31, 2013 (suppl; abstr 603)

21) Mantovani G, Massa E, Dessì A, Dessì M, Orgiano L, Tanca F. Case-control phase II clinical trial to assess efficacy and safety of the same antineoplastic treatment in elderly "fit" compared to adult patients with cancer at different sites. Annals of Oncology, Vol. 23 Suppl.9, September 2012, pag. Ix516-517, 1604P

22) Mantovani G, Massa E, Dessì A, Dessì M, Orgiano L, Tanca F. Case-control phase II clinical trial to assess efficacy and safety of the same antineoplastic treatment in elderly "fit" compared to adult patients with cancer at different sites. XIV Congresso Nazionale AIOM , 27-29 Ottobre 2012. I Supplementi di Tumori Volume 13, Numero 3: S63 abstr C33

23) Dessì M, Madeddu C, Orgiano L, Piras A, Cadeddu C, Antoni G, Serpe R, Mercuro G, Mantovani G. Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers. XIV Congresso Nazionale AIOM , 27-29 Ottobre 2012. I Supplementi di Tumori Volume 13, Numero 3: S113 abstr E20

24) Dessì M, Mantovani G, Madeddu C, Orgiano L, Piras A, Cadeddu C, Antoni G, Serpe R, Mercuro

G. Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers. Annals of Oncology, Vol. 23 Suppl.9, September 2012, pag. ix164, 476P

25) Mantovani G, Dessì M, Piras A, Madeddu C, Orgiano L, Cadeddu C, Antoni G, Mercuro G. Long-term protective effects of the angiotensin receptor blocker Telmisartan on Epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Accepted as Oral Presentation in Patient and Survivor Care Session. ASCO Annual Meeting, Chicago 1-5 June 2012. J Clin Oncol 30, 2012 (suppl; abstr 9006)

26) M. Dessi', C. Madeddu, L. Orgiano, A. Piras, G. Mantovani. Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers. Abstr 1626; WCC 2012-1626, Canada, from 27 – 30 August 2012

27) E. Massa, A. Dessì, M. Dessì, C. Madeddu, L. Orgiano, F. Tanca, G. Astara and G. Mantovani. Case-control phase II clinical trial to assess safety, efficacy of the same antineoplastic treatment(s) in "fit" elderly patients compared to adult patients with cancer at different sites. Accepted for publication in the Abstract Proceedings and as poster to XIII Congresso Nazionale AIOM Bologna, 5-7 Novembre 2011. I Supplementi di Tumori Volume 11, Numero 2: S157 abstr M2, 2011

28) E. Massa, A. Dessì, M. Dessì, C. Madeddu, L. Orgiano, F. Tanca, G. Astara and G. Mantovani. Case-control phase II clinical trial to assess safety, efficacy of the same antineoplastic treatment(s) in "fit" elderly patients compared to adult patients with cancer at different sites. Accepted for publication proceedings 2011 ASCO Annual Meeting, June 3-7 2011, Chicago. J Clin Oncol 29: 2011 (suppl; abstr e19738)

29) Astara G, Orgiano L, Patteri E, Tanca FM, Manca A, Mantovani G. Palliative treatment of peritoneal carcinomatosis: the role of IPHC in a single centre experience. 26th ESHO Annual Meeting, 20-22 th May 2010, Rotterdam, Oral Poster Presentations.

30) Astara G, Deiana L, Dessì M, Massa E, Orgiano L, Patteri E, Pisano M, Mantovani G. Levofloxacin plus Teicoplanin in the treatment of febrile and non febrile neutropenia following cancer chemotherapy: experience of a single institution. Abstracts book XI International Symposium on Febrile Neutropenia, Valencia, 20-21 Febbraio 2009 (Abstr P0014)

31) Astara G, Orgiano L, Patteri E, Tanca FM, Manca A, Mantovani G. Palliative treatment of peritoneal carcinomatosis: the role of IPHC in a single centre experience. Annals of Oncology, Vol. 20 Suppl.8, October 2009, pag. viii66, D37

32) Orgiano L, Astara G, Tanca FM, Patteri E, Manca A, Mantovani M. Palliative treatment of peritoneal carcinomatosis: the role of HIPEC in a single centre experience. Oral presentation at 25th Annual Meeting of the EUROPEAN SOCIETY for HYPERTHERMIC ONCOLOGY (ESHO), Verona 4-6 June 2009

33) Orgiano L, Astara G, Tanca FM, Patteri E, Manca A, Mantovani M. Palliative treatment of peritoneal carcinomatosis: the role of HIPEC in a single centre experience. Oral presentation at 25th Annual Meeting of the EUROPEAN SOCIETY for HYPERTHERMIC ONCOLOGY (ESHO),

Verona 4-6 June 2009

34) Massa E, Astara G, Dessì M, Spiga C, Tanca FM, Madeddu C, Urpis M, Lepori S, Orgiano L, Pala L, Loi C, Mantovani G. Safety and efficacy of hydromorphone OROS in the treatment of moderate-severe pain in opioid naïve cancer patients. Preliminary results of an open prospective phase II study. Abstracts book XI Congress of the European Association for Palliative Care, Vienna, 7-10 Maggio 2009 (Abstr PE 1.F313)

National and International meetings as a Speaker:

1) SimuLung Casi clinici interattivi per la formazione dei GOM nel NSCLC", online, multisede, 9 e 16 aprile 2026
2) LungOnStage Winter 2025. Cagliari, 13 Dicembre 2025
3) SIMULTANEOUS CARE AUTUMN 2025. Cagliari, 22 Novembre 2025
4) TIME 4 LUNG – Ottimizzare la gestione dei processi nella Somministrazione Sottocutanea. Cagliari, 7 ottobre 2025
5) RASSERENIAMOCI - OTTIMIZZAZIONE TERAPEUTICA NELLA GESTIONE DEI PAZIENTI NSCLC CON MUTAZIONE K-RAS, Cagliari 25 settembre 2025
6) YOUNG TALK IN ONCOLOGIA: FOCUS SUL MELANOMA, online virtual, 25/09/2025
7) Lung Innovation. Esperienze cliniche a confronto - 4° Edition. Oristano, 21/03/2024
8) Lung Innovation. Esperienze cliniche a confronto - 3° Edition, 28/09/2023
9) LUNG INNOVATION - esperienze cliniche a confronto (2° edition), 23/02/2023
10) Melanoma 2023 Next Setting Horizon, Roma 28.02.23
11) IMI Young Conference, 2-3rd July 2017, Genova, Italy
12) IMI (Italian Melanoma Intergroup) Masterclass: Management of Metastatic Melanoma: from clinical research to therapy, 17th - 18th March 2017, Cagliari, Italy
13) Breast Cancer Update 2016. 19th November 2016, Cagliari, Italy
14) IMI Young Conference, 4-5th September 2016, Genova, Italy
15) IMI (Italian Melanoma Intergroup) Masterclass: Management of Metastatic Melanoma: from clinical research to therapy, 24th-25th June 2016, Aviano, Italy
16) Workshop on Immunoncology. 6th-7th november 2015, Como, Italy
17) Workshop on Immunoncology. 4th-5th september 2015, Reggio Calabria, Italy
18) AIOM Young Conference: News in oncology, 10th-11st July 2015, Perugia, Italy
19) I IMI Young Conference, 5-6th July 2015, Genova, Italy

20) AIOM Sardinia, Cancer long survivors: clinical and social consequences, 20th May 2015, Sassari, Italy
21) IMI (Italian Melanoma Intergroup) Masterclass: Management of Metastatic Melanoma: from clinical research to therapy, 27th-28th March 2015, Bologna, Italy
22) XI AIOM Sardinia Meeting, Highligths on Melanoma, Thyroid cancer and GIST, 14th-15th November 2014, Alghero, Italy
23) Live with style: influence of life habits on chronic non-communicable diseases, 18th October 2014, Cagliari, Italy
24) XX IMI (Italian Melanoma Intergroup) Meeting, 5th-7th October 2014, Monastier di Treviso, Italy
25) A stain skin: write together a different story, 22nd September 2014, Cagliari, Italy
26) AIOM Sardinia Young Conference: Simultaneous Care for treatment and management of cancer patients, 20th September 2014, Cagliari, Italy
27) IMI (Italian Melanoma Intergroup) Masterclass: Management of Metastatic Melanoma: from clinical research to therapy, 20th-21st June 2014, Livorno, Italy
28) MAME course: Management of Metastatic Melanoma, a clinical report,16th June 2014, Genoa, Italy
29) IMI (Italian Melanoma Intergroup) Masterclass: Management of Metastatic Melanoma: from clinical research to therapy, 9th-10st May 2014, Rionero in Vulture, Italy
30) Immuno-oncology: new therapeutic strategies for management of melanoma patients. 8th April 2014, Genoa, Italy
31) IX AIOM Sardinia Meeting, Clinical management and case report of patient affected by metastatic prostate cancer11th June 2012 Cagliari, Italy
32) 25th Annual Meeting of the EUROPEAN SOCIETY for HYPERTHERMIC ONCOLOGY (ESHO), Palliative treatment of peritoneal carcinomatosis: the role of HIPEC in a single-centre experience. 4-6th June 2009, Verona, Italy

Other meetings:

1) Convegno Nazionale AIOM giovani. Perugia, 7-8 luglio 2017
2) PD-L1 un riferimento emergente nell' Immuno-oncologia. Roma, 18 maggio 2017
3) Scuola Italiana di Immuno Oncologia Toracica. Corso Advanced. Napoli, 28 aprile 2017
4) CTIO: Focus on Lung Cancer. Roma, 19-20 aprile 2017

5) Updates and news from the Genitourinary Cancers Symposium (AIOM post ASCO reviews). Milano, 3 marzo 2017

6) Il ruolo della nanotecnologia in oncologia: presente e futuro. Cagliari, 15 settembre 2016

7) Giornata di aggiornamento sulle neoplasie gastrointestinali: il carcinoma del pancreas e del colon-retto. Cagliari, 13 maggio 2016.

8) Presente e futuro dell' Immuno-Oncologia. Roma, 15-16 aprile 2016

9) Current trends in Immuno-Oncology: Melanoma. Roma, 26-27 febbraio 2016

10) Updates and News from the Gastrointestinal Cancers Symposium in San Francisco, CA, USA. Roma, 5-6 febbraio 2016

11) Carcinoma ovarico recidivante: inquadramento diagnostico e strategie terapeutiche. Cagliari, 18 dicembre 2015

12) Grandangolo 2015: un anno di oncologia. Genova, 30 novembre – 1 dicembre 2015

13) Immuno-oncology course: an overview on treatment and critical issues. Genova, 27 novembre 2015

14) XXI Congresso Nazionale IMI (Intergruppo Melanoma Italiano). Genova, 18-20 ottobre 2015

15) Il carcinoma del colon-retto metastatico tra ricerca e pratica clinica: nuovi aggiornamenti. Cagliari, 10 ottobre 2015

16) European Cancer Congress 2015-ECC. 25-29 settembre 2015, Vienna, Austria

17) AIOM post ASCO review: updates and news from the Annual Meeting in Chicago. Bologna, 12-13 giugno 2015

18) Meet the Professor: la lotta contro i tumori tra cura e sostenibilità. Cagliari, 22 maggio 2015

19) V Corso Nazionale AIOM e SIAPEC-IAP dal laboratorio alla clinica: novità sui biomarcatori. Genova, 13 maggio 2015

20) Immunotargeted-terapia dei tumori, Torino, 16 gennaio 2015

21) Grandangolo 2014. Un anno di oncologia, XVI edizione. Genova, 1-2 dicembre 2014

22) XI Congresso Regionale di Oncologia Medica. Alghero, 14-15 novembre 2014

23) XVI Congresso Nazionale di Oncologia Medica. Roma, 24-26 ottobre 2014

24) Targeted Therapies per il trattamento del melanoma metastatico. Genova, 5-6 settembre 2014

25) Convegno Nazionale AIOM Giovani: 2014 News in Oncology. Perugia, 11-12 luglio 2014

26) Master Course IMI: Management del paziente con melanoma, dalla ricerca alla terapia. Livorno, 20-21 giugno 2014

27) Immuno-oncologia: nuove strategie nella terapia del melanoma. Genova, 8 aprile 2014

28) L'accademia del saper fare. Problematiche internistiche nel pz oncologico.Genova, 6 febbraio 2014

29) 8th World Congress of Melanoma, 17-20 July 2013. Hamburg, Germany

30) Congresso Regionale AIOM Sardegna. Cagliari, 23-24 novembre 2012

31) Grandangolo 2012: un anno di oncologia. XIV edizione, Genova, 13-14 dicembre 2012

32) La nuova opzione terapeutica nel carcinoma mammario Erb B2+. Cagliari, 16 ottobre 2009

33) I corso di aggiornamento SICO in Sardegna. Cagliari, 13 marzo 2009

34) Mediterranean School of Oncology: problemi clinici in medicina palliativa.Cagliari, 20-21 feb 2009

35) III Congresso del Dipartimento di Scienze Mediche Internistiche "Mario Aresu". Cagliari, 12-13 dicembre 2008

36) L'infezione da HBV nel paziente oncologico, onco-ematologico, endocrinologico e reumatologico: una problematica multidisciplinare. Arborea (OR), 29 novembre 2008

37) VIII Congresso Regionale di Oncologia Medica. Cagliari, 21-22 novembre 2008

38) Il Catetere Venoso Centrale, nuove prospettive d'impianto e gestione. Cagliari, 21 ottobre 2008

39) Update nel carcinoma ovarico. Sassari, 18 ottobre 2008

40) VII Congresso Regionale di Oncologia Medica. Cagliari, 6 ottobre 2008

41) Nuove prospettive in Oncologia Medica: focus sui tumori rari e metastasi ossee. Cagliari, 3 ott 2008

42) Terapia antiangiogenica in oncologia: attualità e prospettive future. Cagliari, 27 settembre 2008

43) Workshop on GIST- appropriatezza clinica e integrazione nei processi di cura. Cagliari, 22/05/ 2008

44) II Congresso del Dipartimento di Scienze Mediche Internistiche "Mario Aresu". Cagliari, 14-15 dicembre 2007

45) L' impiego degli oppioidi e le implicazioni bioetiche nella gestione del paziente a fine vita. Cagliari, 30 novembre 2007

46) Focus on innovative locoregional oncotherapies. Mirandola, 19-20 novembre 2007

47) I fattori di crescita emopoietici e la terapia ad alte dosi nel carcinoma della mammella. Cagliari, 23 ottobre 2007

48) L'umanizzazione delle cure in oncologia. Sardara, 23 giugno 2007

49) Congresso Nazionale FCSA. Cagliari, 26 maggio 2007

50) I Congresso del Dipartimento di Scienze Mediche Internistiche "Mario Aresu". Cagliari, 15-16 dicembre 2006

51) Attualità in epatologia. Cagliari, 8-9 settembre 2006.

Si autorizza il trattamento dei dati personali presenti, ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e dell'art. 13 del GDPR (Regolamento UE 2016/679).

Cagliari, 05/06/2026

